Modulation of Cyp450, ALS1 and COX-2 signaling pathways induced by Candida albicans infection via novel antifungal agents

Rehab M Abdel Megeed a,*, Dalia B. Fayed b,1, Amira Abood c,2, Mai O Kadry b,1,*

a Molecular Biology, Therapeutic Chemistry Department, National Research Centre-Dokki, Cairo, Egypt
b Biochemistry, Therapeutic Chemistry Department, National Research Centre-Dokki, Cairo, Egypt
c Microbiology, Chemistry of Natural and Microbial Products Department, National Research Centre-Dokki, Cairo, Egypt

Abstract

Although, fluconazole is widely used in clinical treatment as an antifungal drug, it recorded potential problems as resistance and intracellular accumulation. Female albino mice were injected with single ip dose of Candida albicans (1.5 × 10⁶ CFU). Three weeks post treatment with fluconazole and two novel synthesized compounds [(2-(4-(Pyridin-2-yl) aminosulfonylphenylamino)-6-(naphthalen-2-yl)-4-(pyridin-2-yl) pyridine-3-carbonitrile) and (2-(4-(Pyrimidin-2-yl) aminosulfonylphenylamino)-6-(naphthalen-2-yl)-4-(pyridine-2-yl)pyridine-3-carbonitrile) (13b & 14b, respectively)] in both low and high doses (50 mg/kg & 200 mg/kg), liver function and vaginal inflammation were assessed. Candida albicans significantly elevated serum alanine aminotransferase (ALT) and butrylcholinesterase (BCHE) as well as hepatic malondialdehyde (MDA). Molecular analysis confirmed a significant up-regulation in mRNA gene expression of Agglutinin-like sequence (ALS1), hepatic cytochrome p450 (Cyp450). Vaginal COX-2 gene expression was also elevated. Nevertheless, a significant down-regulation was apparent in mice treated with the aforementioned compounds. Meanwhile, administration of 14b in a high dose noticeably down-regulated the altered parameters expression showing a significant effect in comparison to animals treated with the variable doses of the tested compounds. Histopathological finding confirmed the obtained results. The current work investigated the efficiency of new synthetic pyrimidine derivatives 14bas anti-microbial agents and recommended to be improved and evaluated as a novel antifungal drug to overcome the emergence of resistance problem.

© 2018 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Candida albicans (C. albicans) exist as a normal constituent of the human mucosal microbioloc environment. However, inherited or acquired immunodeficiency syndromes in addition to other factors, such as antibiotics, may cause perturbations in the local mucosal immune environment then develop mucosal candida infections and systemic candidiasis due to translocation of yeast from mucosal surfaces into the systemic circulation (Vazquez and Sobel, 2002). The most common forms of mucosal candidiasis are oropharyngeal candidiasis (OPC) and vulvovaginal candidiasis (VVC) (Smeekens et al., 2013). Human mucosal candidiasis has a substantial global disease burden where, the major of HIV-infected patients develop oral mucosal candidiasis (de Repentigny et al., 2004). Candidiasis reports declared that approximately 75% of healthy reproductive age women develop at least one episode of VVC during their life time (Sobel, 1997).

The largest family of antifungal drugs is azole family that disrupts cell membrane of fungi through inhibiting lanosterol 14-α-demethylase activity (Hof, 2006). Previously, fluconazole has been used extensively for chemoprophylaxis and treatment of systemic fungal infections (Hoffman et al., 2000). Meanwhile, fluconazole resistance has been declared in most of the patients (Redding et al., 2003). Furthermore, some of azole compounds are
C. albicans, then used throughout the study. The organism was main-
tained on Sabouraud dextrose agar (BBL Microbiology Systems, 
Cockeysville, Md.) at 4 °C until use. For each study, two to three 
colonies of the fungus were sub cultured onto fresh potato dex-
trose agar (BBL), and the plates were incubated at 35 °C for 48 h. 
A fungal suspension was prepared by transferring three to four 
colonies of C. albicans to 10 ml of sterile, pyrogen-free normal sal-
ine “0.9% sodium chloride” (Baxter Inc., Chicago, Ill.) and was quan-
tified by hemocytometry. The suspension was diluted with normal 
saline to a final concentration of 1.5 \times 10^6 organisms per ml. Mor-
phologic examination revealed that >95% of the organisms were 
blastoconidia. The viability of the yeast was >90% by trypan blue 
exclusion analysis (Louie et al., 1998).

2.4. Animals

Female albino mice, weighing 18–22 gm, obtained from the ani-
mal house of National Research Center were used in this study. 
Animals were housed in cages kept at standardized conditions (2 
2 ± 5 °C, 55 ± 5% humidity, and 12 h light/dark cycle). They were 
allowed free access to water and pelleted standard chow diet. All 
procedures relating to animal care and treatments strictly adhered 
to the ethical procedures and policies approved by Animal Care and 
Use Committee of National Research Center (12-038), and com-
plied with the Guide for Care and Use of Laboratory published by 
the US National Institute of Health.

2.5. Experimental design

After one week of acclimatization, animals were randomly 
divided into 8 groups (10 mice each) 

Group 1: Received DMSO and served as negative control. 
Group 2 to 8: Animals were infected with C. albicans; intraperi-
toneously 0.5 ml of the previously prepared concentration (1.5 \times 
10^6 organisms per ml). After 2 days post – infection, the follow-

ing was applied (Louie et al., 1998) 

Group 2 (Candida group): +ve control C. albicans infected ani-

cimals were left untreated. 
Group 3: C. albicans infected animals were treated with low 
dose (50 mg/kg/day); as previously described by Sun et al. 
(2006) of reference antifungal drug (fluconazole) for consecu-
tive three weeks. 
Group 4: C. albicans infected animals were treated with low 
dose (50 mg/kg/day) of new synthesized chemical compound 
(13b) for consecutive three weeks (Sun et al., 2006) 
Group 5: C. albicans infected animals were treated with low 
dose (50 mg/kg/day) of new synthesized chemical compound 
(14b) for consecutive three weeks (Kotb et al., 2015). 
Group 6: C. albicans infected animals were treated with high 
dose (200 mg/kg/day) of fluconazole for consecutive three 
weeks (Sun et al., 2006). 
Group 7: C. albicans infected animals were treated with high 
dose (200 mg/kg/day) of (13b) for consecutive three weeks 
(Kotb et al., 2015). 
Group 8: C. albicans infected animals were treated with high 
dose (200 mg/kg/day) of (14b) for consecutive three weeks 
(Kotb et al., 2015). 

Note: All utilized drugs (fluconazole, 13b and 14b) were dis-
olved in DMSO as a solvent.

2.6. Sample preparation

At the end of the experiment all groups were sacrificed and 
blood samples were taken from each animal by puncture of the 
sublingual vein into sterilized tubes and let stand for 10 min to
clot. Serum was separated by centrifugation at 3000 rpm for 10 min and kept at −80 °C for further terminations. In the same time, vagina and liver were removed carefully then rinsed with cold saline (0.9% sodium chloride), and homogenized in 50 mM phosphate buffer, pH 7.4 (1:5 w/v). The homogenate was centrifuged at 3000 rpm for 10 min at 4 °C to separate cell debris. The supernatant was stored at −80 °C for subsequent biochemical determinations.

2.7. Microbiological examination

Sections from liver and vaginal tissue were weighed, suspended in 2.0 ml of saline solution and homogenized by a motor driven homogenizer. Undiluted and 1000-fold diluted 0.1-ml samples of organ homogenates were streaked onto plates of Sabouraud dextrose agar and incubated at 35 °C for 48 h. The number of colonies was counted, and the number of viable organisms per ml was determined. The homogenates were also applied to the surface of hemocytometer glass slides and examined microscopically (Louie et al., 1998).

2.8. Biochemical analysis

2.8.1. Serum aspartate aminotransferases (AST) and alanine transaminase (ALT) activity

AST and ALT activity were estimated spectrophotometrically using commercially available kits provided from Randox Company (United Kingdom, Antrim; AS2359). In brief, in presence of AST, L-aspartate forms oxaloacetate and L-glutamate. In alkaline solution, the formed oxaloacetate reacts with 2,4-dinitrophenyl hydrazine to give the hydrazone derivative that can be measured spectrophotometrically at 540 nm (Reitman and Frankel, 1957).

2.8.2. Hepatic malondialdehyde (MDA) level

MDA, as an index of lipid peroxidation, was measured using kit provided by Randox Company (Antrim, UK). MDA reacts with thiobarbituric acid (TBA) in acid medium giving a pink-colored complex that can be measured spectrophotometrically at 520 nm and 535 nm, using 1, 1, 3, 3-tetramethoxy propane as standard (Ohkawa et al., 1979).

2.8.3. Hepatic butyrylcholinesterase (BCHE) activity

BCHE was estimated spectrophotometrically in homogenate using commercially available kits provided from Randox Company.

2.9. Molecular analysis (real time PCR)

Target genes expression analyses were detected using real-time PCR according to specific forward and reverse primers for Cyp 450, ALS1 and COX-2 (all primers sequences are listed in Table 1). Firstly total RNA was extracted from liver and vagina samples using SV total RNA isolation system (Promega, Madison, WI), then Extracted RNA reverse transcribed into cDNA and amplified by PCR using RT-PCR kit (Stratagene, USA). Reactions were performed in a 50 μL final volume (25 μL SYBR Green Mix (2x), 0.5 μL cDNA, 2 μL primer pair mix (5 pmol/μL each primer), 22.5 μL H2O), PCR reaction was: 50 °C for 2 min (1 cycle), 95 °C for 10 min (1 cycle) and 95 °C for 15 s, 45 to 60 °C for 30 s (according to optimum annealing temperature for each gene) and 72°C for 30 s (40 cycles) then 72°C for 10 min (1 cycle). Data from the real-time assays were calculated by Sequence Detection Software version 1.7 (PE Biosystems, Foster City, CA, USA) (Tago et al., 2001; Sun et al., 2006; Murciano et al., 2012).

2.10. Histopathological examination

Paraffin embedded samples were prepared for sectioning at 4-μm thickness. Slides were stained with hematoxylin and eosin and examined by light microscope (Bancroft and Stevens, 1996).

2.11. Statistical analysis

Data were expressed as means ± SEM. Statistical analysis was performed using Instat-3 computer program (Graph Pad Software Inc., San Diego, CA). One-way analysis of variance was performed by SPSS 12 program followed by post hoc test. The level of significance was set at p < .05 using Tukey’s test.

3. Results

3.1. C. albicans viability in target organs

As demonstrated in Fig. 1, C. albicans count was significantly high in the candida group. After the treatment with the three drugs, the progression of the fungi was mitigated. In liver tissues it was clear that 14b treated group displayed the most pronounced effect in reducing candida count. On the other hand, the reference drug fluconazole declared the most significant improvement in the vaginal tissue treatment as compared to the other groups. Moreover, 14b treated group high dose nearly approached the value of the fluconazole treated group.

3.2. Inhibition of Candida-induced liver injury

As shown in Fig. 2, candida infection significantly increased serum ALT level by 180.8% as compared to the control value. On the other hand, in groups treated with fluconazole, 13b and 14b either low or high doses the level of liver enzyme was comparatively lower than that of Candida intoxicated group, implying the possible therapeutic effects of these agents on liver injury. Interestingly, the tested parameter was reverted back to near normal when 14b compound was administrated in a high dose. Data represented in Fig. 2 declared significant elevation in serum AST level by almost 234%. However, non significant modulation was declared within all groups.

3.3. Modulation of oxidative stress biomarkers

C. albicans infection induced a state of oxidative stress evidenced by an elevation in hepatic MDA along with an increment of butyrlcholinesterase level reaching 216.8% and 520.5%, respectively as compared to the control value (Fig. 3). Administration of fluconazole, 13b and 14b at low dose significantly reduced MDA values as compared to Candida group. Obviously, fluconazole high dose and 14b regimens reduced MDA and butyrlcholinesterase level by almost 3-fold relative to candida group, displaying thus the most pronounced effect.

3.4. Modulation of liver inflammation

Data recorded in Fig. 4 declared that C. albicans infection caused a significant up-regulation in mRNA gene expression of ALS1 by almost 8 folds as compared with the −ve control group. On the other hand, a significant down regulation was demonstrated in all treated groups. Besides, 14b high dose regimen recorded the most significant reduction reaching the normal value (see Fig. 4). The data in Fig. 4 indicated that C. albicans infection caused a significant up-regulation in mRNA gene expression of Cyp450 by almost 14 folds as compared to the control value. Nevertheless, a
significant down-regulation was apparent in mice treated with fluconazole, 13b and 14b. Besides, 13b and 14b high doses regimen considerably reversed the level of Cyp450 back near to the normal value.

### Table 1
Oligonucleotide primer sequence of Cyp450, ALS1, COX-2 and β-actin (ACT1).

| Gene name     | Forward primer  | Reverse primer    |
|---------------|-----------------|-------------------|
| Cyp450        | 5’AAGCGCTTCGGCCAG3’ | 5’TAGCCATGCAGCCACCAG3’ |
| ALS1          | 5’CCTATTCGACTAAGACACC3’ | 5’ACAGTTGATTTGGCGACTGGA3’ |
| COX-2         | 5’CAGGGACACTGGAACATTG3’ | 5’ACCAGGTCTCGGTGTATGGA3’ |
| β-actin (ACT1)| 5’CGTTGTTCCAATTTACGCGT3’ | 5’TGTTGAAATCAAGCGAACC’ |

**Fig. 1.** Effect of new synthetic compounds and fluconazole on *C. albicans* counting in liver and vaginal tissues. Data are expressed as means ± SEM (n = 10). *p* < .05 is considered significant. Groups having the same letter are not significantly different from each other, while those having different letters are significantly different from each other.

**Fig. 2.** The effect of new synthetic compounds and fluconazole on ALT and AST enzymes activity in *C. albicans* infected groups. Data are expressed as means ± SEM (n = 10). *p* < .05 is considered significant. Groups having the same letter are not significantly different from each other, while those having different letters are significantly different from each other.

3.5. Modulation of vaginal inflammation

A significant elevation in the vaginal inflammatory marker Cox-2 gene expression post *C. albicans* infection was recorded.
Administration of fluconazole, 13b and 14b revealed a significant down-regulation in the gene expression of Cox-2 as compared to the control value. Meanwhile, administration of 14b in a high dose noticeably down-regulated its expression showing a significant effect in comparison to animals treated with the variable doses of the tested compounds (Fig. 5).

In general from data listed, it was obviously that 13b at low dose revealed an oxidative stress as compared with the other tested groups for both MDA and butyrylcholinesterase level.

3.6. Histopathological examination

Fig. 6 declared vaginal tissue Sections (2) showed candida group with atrophic epithelial layer in proximal and central part of vagina, candidiasis showing many hyphae in the lumen. (3) fluconazole treated group with healed almost normal epithelial layer in proximal and central part of vagina, candidiasis showing few hyphae in the lumen. (4) 13b treated group in a low dose with moderately healed epithelial layer in proximal and central part of vagina, no hyphae in the lumen. (5) 14b treated group in a low dose with almost normal epithelial layer in proximal and central part of vagina, candidiasis showing few hyphae in the lumen. (6) fluconazole high dose treated group with healed normal epithelial layer in proximal and central part of vagina, candidiasis showing few hyphae in the lumen. (7) 13b high dose declared normal epithelial layer in proximal and central part of vagina, candidiasis showing few hyphae in the lumen. (8) 14b in a high dose declared normal epithelial layer in proximal and central part of vagina, candidiasis showing few hyphae in the lumen.
Fig. 5. Effect of fluconazole, 13b and 14b on vaginal COX-2 gene expression in *C. albicans* infected groups. Data are expressed as means ± SEM (n = 10). *p* < .05 is considered significant. Groups having the same letter are not significantly different from each other, while those having different letters are significantly different from each other.

Fig. 6. Histopathological examination for vaginal female mice showing sections 1, 2, 3, 4, 5, 6, 7 & 8 where (1) is -ve control (healthy group), (2) is candida (Candida group), (3, 4, & 5) are treated groups with low dose of fluconazole, 13b and 14b, respectively. (6, 7, & 8) are treated groups with high dose of fluconazole, 13b and 14b, respectively.
4. Discussion

Although fluconazole is the most commonly used drug for *C. albicans* treatment, lots of problems were associated with fluconazole administration as resistance and accumulation in the body that influence several inflammation reactions along with affecting function of different organs (Elizabeth and Shawn (2017); Popp et al. 2017). Previously, some studies elucidated the ability of triazoles to induce hepatic cytochromes (Cyps) which play a vital role in the metabolism of azole drugs in the liver (Somchit et al., 2004; Sun et al., 2006).

Different available antimicrobial drugs are composed of naphthalene nucleus such as naacillin, naftifine, tolnaftate and terbinafine (Rokade and Sayyed, 2009). These antifungal drugs are used for treatment of tinea pedis, tinea cruris and tinea corporis (Desai et al., 2012). It affects bactericidal activity via inhibition of bacterial cell wall synthesis by binding one or more of the penicillin binding proteins (PBPs) (Overington et al., 2006). Previously, pyridine was reported as antimicrobial agent. It inhibits folate synthesis which is responsible for DNA and RNA synthesis in bacteria. So it inhibits cell division. Furthermore it is a competitive inhibitor of the bacterial enzyme dihydropteroate synthase (Jmning et al., 2006; McDonald et al., 2009). In the present study, assessment of the efficiency of the new synthetic compounds (13b and 14b) that are formed of a combination of both naphthalene and pyridine moieties in order to overcome the resistant problems associated with traditional antifungal drugs in marketing is carried out.

The current study revealed that *C. albicans* infection elevated serum ALT and AST activities as well as butyrylcholinesterase as compared to the control value. Increased liver enzymes were pointed to cellular leakage indicating liver damage. It has been previously demonstrated that numerous liver function tests were altered post *C. albicans* infection (Minemura et al., 2014). In addition to hepatic MDA elevation indicating oxidative stress induced by *C. albicans*.

Treatment with fluconazole exhibited a significant increment in ALT liver marker as compared to candida group specially in high dose. This elevation suggested hepatic toxicity of fluconazole (Khoza et al., 2017). On the other hand, treatment with 13b and 14b exhibited a significant reduction in ALT as compared to Candida group. This reduction reflected the hepato-protective effect of these agents.

As previously reported, azole class antifungal drugs inhibit fungal CYP450 14z-demethylase, as this interrupts the conversion of lanosterol to ergosterol, a component of the fungal cell membrane (Hof, 2006). Furthermore, correlation between fluconazole dose,
the extent of hepatic hypertrophy, the levels of Cyp450 expression, and Cyp450 mediated enzymatic activities was also investigated (Lee et al., 2009). Here in, an elevation in Cyp450 in C. albicans intoxicated group was observed. Nevertheless, a significant down-regulation was apparent in mice treated with fluconazole, 13b and 14b. Besides, 13b and 14b high doses regimen considerably reversed the level of Cyp 450 back near to the normal value indicating hepatotoxic effect of fluconazole and demonstrated the efficiency of the new synthetic compounds 13b and 14b in regulation of Cyp 450 gene expression.

C. albicans has multiple factors that cause disease. These factors includes phenotypic switching, adherence and secreted hydrolysces. They are regulated by different genes, particularly the agglutinin-like sequence (ALS), secreted aspartyl protease, and lipase families which are involved in the pathogenesis and adhesion of C. albicans to mucosa and epithelial cells (Hoyer et al., 2008). In the current study C. albicans infection caused a significant up-regulation in mRNA gene expression of ALS1 as compared to the control value. This finding was previously reported by Murciano et al., 2012 as an elevation in C. albicans ALS1 proteins expression in human oral epithelial cells. Moreover, a significant down regulation was demonstrated in all treated groups with the superiority of 14b high dose regimen.

Oxidative stress has been linked to intracellular MAP kinase signaling pathways which lead to up-regulation of COX-2 gene expression (Tago et al., 2001). In this concept, we investigated an elevation in vaginal COX-2 gene expression post C. albicans infection. Previously, it has been reported that COX-2 induction occurs following C. albicans infection (Lee et al., 2009). Moreover, modulation of COX-2 gene expression in all treated groups with the superiority of 14b high dose was observed. This finding indicated the efficiency of 14b as anti fungal agent. It is well known that C. albicans ability to establish a persistent infection depends on signals that regulate release of factors from target cells responsible for replication of pathogen. This cell signaling is designed to serve the purpose of cell survival for both host and pathogen. Infection by C. albicans of host tissue and cells is mediated through surface receptors, such as mannose, glucan, integrins, etc. (Castro et al., 1996) and has been found to release pro inflammatory cytokines and large amount of arachidonic acid (AA) from host cells. AA is subsequently converted by lipoxigenases and cyclooxygenases (COXs) to eicosanoids (Noverr et al., 2001).

The antiinflammatory effect of pyridine derivativates has been previously reported via prostaglandin-2 reduction (Mohamed et al., 2010). Naphthalene is important aryl ring in many active compounds such as anti-inflammatory, anti-bacterial, anti-microbial and anti-cancer. In recent trends, heterocycles plays a major role in drug synthesis (Sharma and Singh, 2006). Pyrazole derivatives have been the subject of substantial attention by synthetic and medicinal chemists due to their role in many biological activities such as anti cancer, antiviral, anti-inflammatory, antifungal, antimicrobial, antihistaminic, antiplatelet and analgesic activities. The mechanism of action for this compounds is linked to the non-selective or selective inhibition of two cyclooxygenase isomor, COX-1 & COX-2 (Feixas and Jimenez, 2011).

Animals given new synthetic compounds 13b, 14b showed histopathological findings in line with normal mucosal recovery from the induced infectious process thereby, confirming the therapeutic efficiency of these compounds as antifungal agents.

5. Conclusion

From the current investigation, it could be concluded that the combination of pyridine and Naphthalene derivatives (principally 14b in a high dose) could be used as a novel antifungal agents to treat important fungal infections caused by C. albicans. So it is recommended to be improved and evaluated as a novel antifungal drug with less effect on liver function and able to overcome the emergence of the resistance problem.

Acknowledgment

Acknowledgment is directed to prof. Dr. Laila Rashed, professor of Biochemistry Faculty of medicine, Cairo University for technical aid, and Dr. Yasmin Syam, researcher of Therapeutic Chemistry Department, National Research Center for providing new chemical antifungal agents.

Conflict of interest

The authors have no conflicts of interest to declare.

References

Athikomkulchai, S., Prawatt, H., Thasana, N., Rungsurungs, N., Reichratt, S., 2006. COX-1, COX-2 inhibitors and antifungal agents from Croton hutchinsonianus. Chem. Pharm. Bull. (Tokyo) 54, 262–264.

Bancroft, J.D., Stevens, A., 1996. Theory and practice of histological techniques. Churchill Livingstone, London. 163.

Castro, M., Bojarke, J.A., Rorbach, M.S., Limper, A.H., 1996. Candida albicans induces the release of inflammatory mediators from human peripheral blood monocytes. Inflammation 20, 107–122.

de Repentigny, L., Lewandowski, D., Jolicoeur, P., 2004. Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection. Clin. Microbiol. Rev. 17, 729–759. https://doi.org/10.1128/CMR.17.4.729-759.2004.

de table of contents.

Desai, N.C., Shihora, P.N., Rajpara, K.M., Joshi, V.V., Vaghani, H.V., Satodya, H.M., Dodiya, A.M., 2012. Synthesis, characterization, and antimicrobial evaluation of novel naphthalene-based 1,2,4-triazoles. Med. Chem. Res. 21, 2981–2989. https://doi.org/10.1007/s00041-011-9833-8.

Elizabeth, L.B., Shaw, R.L., 2017. Flucconazole resistance in Candida species: a current perspective. Infect. Drug Resist. 10, 237–245. 10.2147/IDR.S118892.

Fu, Y., Ibrahim, A.S., Sheppard, D.C., Chen, Y.-C., French, S.W., Cutler, J.E., Filler, S.G., Edwards, J.E., 2002. Candida albicans Als1p: an adhesin that is a downstream effector of the EFG1 filamentation pathway. Mol. Microbiol. 44, 61–72.

Feixas, Joan, Jimenez, Juan-Miguel, 2011. Naphthalene derivatives: a new series of selective cyclooxygenase-2 inhibitors. Bioorg. Med. Chem. Lett. 11, 2687–2690.

Hof, H., 2006. A new, broad-spectrum azole antifungal: posaconazole–mechanisms of action and resistance, spectrum of activity. Mycoses 49 (Suppl 1), 2–6. https://doi.org/10.1111/j.1439-0507.2006.01295.x.

Hoffman, H.L., Ernst, E.J., Klepsier, M.E., 2000. Novel triazole antifungal agents. Expert Opin. Invest. Drugs 9, 593–605. https://doi.org/10.1517/13543784.9.3.593.

Hoyer, L.L., Green, C.B., Oh, S.-H., Zhao, X., 2008. Discovering the secrets of the Candida albicans agglutinin-like sequence (ALS) gene family—a sticky pursuit. Med. Mycol. 46, 1–15. https://doi.org/10.1080/13093780701435317.

Imming, P., Sinning, C., Meyer, A., 2006. Drugs, their targets and the nature and emergence of the resistance problem. J. Toxicol. 2017, 6746989. https://doi.org/10.1155/2017/6746989.

Kobayashi, K., Urashima, K., Shimada, N., Chiba, K., 2002. Substrate specificity for rat cytochrome P450 (CYP) isoforms: screening with cDNA-expressed systems of the rat. Biochem. Pharmacol. 63, 889–896.

Koth, E.R., Anwar, M.M., Syam, Y.M., Bagato, O., Abdelmoh, S., 2015. Available Online through Research Article Synthesis of Novel Naphthalene-pyridine Hybrid Compounds for Anti-avian Influenza Virus (h5n1) and Antimicrobial Evaluation, vol. 7, pp. 8237–8273.

Lee, H., Lee, C., Yang, C., Su, S., Salter, D.M., 2009. Research Article Candida Albicans 2 Expression and Prostaglandin E2 Production in Synovial Fibroblasts through an Extracellular-regulated Kinase 1/2 Dependent Pathway, vol. 11, pp. 1–9. http://doi.org/10.1186/ar2661.

Louie, A., Drusano, G.L., Banerjee, P., Liu, Q.F., Liu, W., Kaw, P., Shayegani, M., Taber, H., Miller, M.H., 1998. Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob Agents Chemother. 42, 1105–1109.

Marchaim, D., Lemanek, L., Bheemreddy, S., Kaye, K.S., Sobel, J.D., 2012. Fluconazole-resistant Candida albicans vulvovaginitis. Obstet. Gynecol. 120, 1407–1414. https://doi.org/10.1097/OGC.0b013e31827307b2.

McDonald, M., Mannion, C., Rafter, P., 2009. A confirmatory method for the simultaneous extraction, separation, identification and quantification of Tetracycline, Sulphonamide, Trimethoprim and Dapsone residues in muscle by ultra-high-performance liquid chromatography-tandem mass spectrometry.
spectrometry accord. J. Chromatogr. A 1216, 8110–8116. https://doi.org/10.1016/j.chroma.2009.05.092.

Minemura, M., Tajiri, K., Shimizu, Y., 2014. Liver involvement in systemic infection. World J. Hepatol. 6, 632–642. https://doi.org/10.4253/wjh.v6.i9.632.

Mohamed, A., Al-Omar, Abd El-Galil, E., Amr, Rashad, A., Al-Salahi, 2010. Anti-inflammatory, analgesic, anticonvulsant and antiparkinsonian activities of some pyridine derivatives using 2,6-disubstituted isonicotinic acid hydrazides. Arch. Pharm. Chem. Life Sci. 10, 648–656.

Murciano, C., Moyes, D.L., Runglall, M., Tobouti, P., Islam, A., Hoyer, L.L., Naglik, J.R., 2012. Evaluation of the role of Candida albicans agglutinin-like sequence (Als) proteins in human oral epithelial cell interactions. PLoS One 7, e33362. https://doi.org/10.1371/journal.pone.0033362.

Noverr, M.C., Phare, S.M., Toews, G.B., Coffey, M.J., Huffnagle, G.B., 2001. Pathogenic yeasts Cryptococcus neoformans and Candida albicans produce immunomodulatory prostaglandins. Infect. Immun. 69, 2957–2963. https://doi.org/10.1128/IAI.69.5.2957-2963.2001.

Ohkawa, H., Ohishi, N., Yagi, K., 1979. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 95, 351–358.

Overington, J.P., Al-Lazikani, B., Hopkins, A.L., 2006. How many drug targets are there? Nat. Rev. Drug Discov. 5, 993–996. https://doi.org/10.1038/nrd2199.

Popp, C., Hampe, I.A.L., Hertlein, T., Ohlsen, K., Rogers, P.D., Morschhäuser, J., 2017. Competitive fitness of fluconazole-resistant clinical candida albicans strains. Antimicrob. Agents Chemother. 27 61 (7). doi: 10.1128/AAC.00584-17.

Redding, S.W., Kirkpatrick, W.R., Saville, S., Coco, B.J., White, W., Forthgill, A., Rinaldi, M., Eng, T., Patterson, T.F., Lopez-Ribot, J., 2003. Multiple patterns of resistance to fluconazole in Candida glabrata isolates from a patient with oropharyngeal candidiasis receiving head and neck radiation. J. Clin. Microbiol. 41, 619–622.

Reitman, S., Frankel, S., 1957. A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Am. J. Clin. Pathol. 28, 56–63.

Rokade, Y.B., Sayyed, R.Z., 2009. Naphthalene derivatives : a new range of antimicrobials with high therapeutic value. RASAYAN J. Chem. 2, 972–980.

Somchit, N., Norshahida, A.R., Hasiah, A.H., Zuraini, A., Sulaiman, M.R., Noordin, M., 2004. Hepatotoxicity induced by antifungal drugs itraconazole and fluconazole in rats: a comparative in vivo study. Hum. Exp. Toxicol. 23, 519–525. https://doi.org/10.1191/0960327104ht479oa.

Sun, C., Thai, S.-F., Lambert, G.R., Wolf, D.C., Tully, D.B., Goetz, A.K., George, M.H., Grindstaff, R.D., Dix, D.J., Nesnow, S., 2006. Fluconazole-induced hepatic cytochrome P450 gene expression and enzymatic activities in rats and mice. Toxicol. Lett. 164, 44–53. https://doi.org/10.1016/j.toxlet.2005.11.015.

Tago, K., Funakoshi, M., Mano, H., Yanagisawa, K., Hayakawa, M., Kurokiwa, K., Iwahana, H., Kasahara, T., Tominaga, S., 2001. Presence of a genistein-responsive inhibitory mechanism on interleukin-1alpha-induced NF-kappaB activation. Eur. J. Biochem. 268, 6526–6533.

Vazquez, J.A., Sobel, J.D., 2002. Mucosal candidiasis. Infect. Dis. Clin. North Am. 16, 793–820. v.